This inventor holds 57 USPTO granted patents and 12 published patent applications, plus 3 CIPO patents and 5 EPO patents, primarily in Macrophage Migration Inhibitory Factor (CPC class C07D). Top assignees: The Picower Institute for Medical Research, Yale University, The Rockefeller University. Active years: 1997-2023.
Inventors with similar research interests:
Location History:
- New York, NY (US) (1997 - 2006)
- New Haven, CT (US) (2020)
- Greenwich, CT (US) (2020)
- Cos Cob, CT (US) (1998 - 2023)
Company Filing History:
30 out of 67 
7 out of 1,365 
6 out of 751 
Years Active: 1997-2023
Areas of Expertise:
Title: Richard J Bucala: Pioneering Innovations in Medical Research
Introduction
Richard J Bucala is an accomplished inventor based in Cos Cob, CT, USA, known for his significant contributions to the field of medical research. With an impressive portfolio of 57 patents, Bucala has dedicated his career to developing novel therapeutic strategies addressing critical health issues through innovative approaches.
Latest Patents
Among his latest inventions, Bucala has developed MIF modulators, which involve novel heterocyclic compounds and pharmaceutical compositions aimed at modulating levels of MIF (macrophage migration inhibitory factor) expression. This invention has implications for treating disorders associated with abnormal MIF levels. Another key patent focuses on the uses of parasite macrophage migration inhibitory factors, relating to compositions, such as vaccine formulations, that provide protective immunity against parasitic infections. These compositions comprise nucleic acids encoding MIF antigens, parasite MIF antigens, or antibodies binding specifically to these antigens, showcasing Bucala’s innovative approach to combating diseases caused by parasitic protozoans and helminths.
Career Highlights
Throughout his career, Richard J Bucala has worked with prestigious institutions including The Picower Institute for Medical Research and Yale University. His research has significantly advanced the understanding of immune responses and their roles in various diseases, particularly those related to parasitic infections.
Collaborations
Bucala has collaborated with notable scientists, including Anthony Cerami and Helen Vlassara, contributing to a dynamic exchange of ideas and fostering advancements in the medical research community. These collaborations have resulted in impactful innovations that continue to enhance therapeutic strategies in immunology and infectious diseases.
Conclusion
In summary, Richard J Bucala's extensive patent portfolio and collaborative efforts illustrate his commitment to innovation in medical research. His inventions continue to pave the way for new treatments for disorders influenced by MIF expression, making a lasting impact on the field of healthcare and biotechnology.